Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 2/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4608967 | 0.83 | DRD3 (0.54) | GRIN2BGRIN2AKCNH2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7322276 | 0.82 | KCNH2 (0.56) | GRIN2BGRIN2AKCNH2 | |
| Hydrochloric Acid SCHEMBL7322321 | 0.80 | KCNH2 (0.58) | GRIN2BGRIN2AKCNH2 | |
| Hydrochloric Acid SCHEMBL7322849 | 0.80 | KCNH2 (0.56) | GRIN2BGRIN2AKCNH2 | |
| Hydrochloric Acid SCHEMBL7324295 | 0.74 | GRIN2B (0.63) | GRIN2BGRIN2AKCNH2ALDH1A1 | |
| SCHEMBL4608739 | 0.74 | GRIN2B (0.52) | GRIN2BGRIN2AKCNH2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7323720 | 0.73 | HTR1A (0.53) | GRIN2BALDH1A1 | |
| Hydrochloric Acid SCHEMBL9151919 | 0.72 | GRIN2B (0.57) | GRIN2BGRIN2AALDH1A1 | |
| SCHEMBL4608233 | 0.70 | KCNH2 (0.40) | KCNH2ALDH1A1 | |
| SCHEMBL18737492 | 0.69 | DRD2 (0.51) | KCNH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1272187-B1 | DOPAMINE-D3 RECEPTOR LIGANDS FOR THE TREATMENT OF ADDICTION | ABBOTT GMBH & CO KG (DE) | 2008-07-30 | — | — | EP | claimed |
| EP-1272187-B1 | DOPAMINE-D3 RECEPTOR LIGANDS FOR THE TREATMENT OF ADDICTION | ABBOTT GMBH & CO KG (DE) | 2008-07-30 | — | — | EP | disclosed |
| US-20030087917-A1 | Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087917-A1 | Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system | DRD3, DRD2, OPRD1 | GRIN2B 30/4885GRIN2A 59/4885KCNH2 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.